Search research articles
Contact Us
Filters
Showing results (231-240 of 271) with videos related to
Page
of 28
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 1, 1997
Post-remission therapy of adult acute myeloid leukaemia: one cycle of high-dose versus standard-dose cytarabine. Leukaemia Project Group of the Swiss Group for Clinical Cancer Research (SAKK)
M Fopp, M F Fey, M Bacchi, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 25, 2004
The leukemic fusion gene AML1-MDS1-EVI1 suppresses CEBPA in acute myeloid leukemia by activation of Calreticulin
Daniel Helbling, Beatrice U Mueller, Nikolai A Timchenko, et al.
Leukemia & Lymphoma
|
October 24, 2000
Divergent expression of cyclin-dependent kinase inhibitors (CKI) and p14ARF/p16 beta in non-Hodgkin's lymphomas and chronic lymphocytic leukemia
T Pabst, U R Peters, M Tinguely, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 18, 1998
Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Swiss Group for Clinical Cancer Research (SAKK)
D C Betticher, D Ratschiller, S F Hsu Schmitz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 13, 2000
Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK)
R Morant, J Bernhard, R Maibach, et al.
International Journal of Cancer
|
August 30, 2000
Differential expression of p73 splice variants and protein in benign and malignant ovarian tumours
D Zwahlen, M P Tschan, T J Grob, et al.
Breast Cancer Research and Treatment
|
January 13, 2009
Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century
Olivia Pagani, Karen N Price, Richard D Gelber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 16, 2003
Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV
Diana Crivellari, Karen Price, Richard D Gelber, et al.
Oncogene
|
December 5, 1998
Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression
S Vonlanthen, J Heighway, M P Tschan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 1998
Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma
D C Betticher, A von Rohr, D Ratschiller, et al.
Page
of 28
Search research articles
Search
Showing results (231-240 of 271) with videos related to
Sort By:
Page
of 28
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 1, 1997
Post-remission therapy of adult acute myeloid leukaemia: one cycle of high-dose versus standard-dose cytarabine. Leukaemia Project Group of the Swiss Group for Clinical Cancer Research (SAKK)
M Fopp, M F Fey, M Bacchi, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 25, 2004
The leukemic fusion gene AML1-MDS1-EVI1 suppresses CEBPA in acute myeloid leukemia by activation of Calreticulin
Daniel Helbling, Beatrice U Mueller, Nikolai A Timchenko, et al.
Leukemia & Lymphoma
|
October 24, 2000
Divergent expression of cyclin-dependent kinase inhibitors (CKI) and p14ARF/p16 beta in non-Hodgkin's lymphomas and chronic lymphocytic leukemia
T Pabst, U R Peters, M Tinguely, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 18, 1998
Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Swiss Group for Clinical Cancer Research (SAKK)
D C Betticher, D Ratschiller, S F Hsu Schmitz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 13, 2000
Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK)
R Morant, J Bernhard, R Maibach, et al.
International Journal of Cancer
|
August 30, 2000
Differential expression of p73 splice variants and protein in benign and malignant ovarian tumours
D Zwahlen, M P Tschan, T J Grob, et al.
Breast Cancer Research and Treatment
|
January 13, 2009
Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century
Olivia Pagani, Karen N Price, Richard D Gelber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 16, 2003
Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV
Diana Crivellari, Karen Price, Richard D Gelber, et al.
Oncogene
|
December 5, 1998
Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression
S Vonlanthen, J Heighway, M P Tschan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 1998
Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma
D C Betticher, A von Rohr, D Ratschiller, et al.
Page
of 28